Takeda Pharmaceutical Company Limited (TAK)
| Market Cap | 60.57B +29.6% |
| Revenue (ttm) | 28.42B +3.1% |
| Net Income | -1.01B |
| EPS | -0.64 |
| Shares Out | 1.58B |
| PE Ratio | n/a |
| Forward PE | 20.21 |
| Dividend | $0.49 (2.61%) |
| Ex-Dividend Date | Mar 31, 2026 |
| Volume | 2,737,923 |
| Open | 18.82 |
| Previous Close | 18.59 |
| Day's Range | 18.77 - 18.91 |
| 52-Week Range | 12.99 - 19.10 |
| Beta | 0.10 |
| Analysts | Strong Buy |
| Price Target | 22.04 (+16.86%) |
| Earnings Date | Oct 29, 2026 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enan... [Read more]
Analyst Summary
According to 3 analysts, the average rating for TAK stock is "Strong Buy." The 12-month stock price target is $22.04, which is an increase of 16.86% from the latest price.
News
Roche proposes former Takeda CEO for board seat
Roche on Wednesday said it was proposing Christoph Weber, the former CEO of Takeda Pharmaceuticals , for election to the Swiss company's board of directors at its AGM next March.
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Onco...
Takeda Unveils $22.2 Mln CSR Collaborations Focused On Climate-Resilient Health; Stock Up
(RTTNews) - Takeda Pharmaceutical Company Ltd. (TAK), a commercial-stage pharmaceutical company announced that it has granted $22.2 million to four new Corporate Social Responsibility (CSR) partners t...
Dengue vaccine to hit market by first half of 2027
India News: NEW DELHI: India's first dengue vaccine is expected to be available in the private market in the first half of 2027. Takeda Pharma and Dr Reddy's Labo.
Takeda Employees Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partner...
India's Dr Reddy's inks distribution agreement with Takeda for dengue vaccine in India
Dr Reddy's Laboratories said on Friday it signed a deal with Takeda Pharmaceutical Company for the promotion and distribution of the Qdenga dengue vaccine in India.
Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation Officer Lauren Duprey Sells ...
Takeda Pharmaceutical (TAK) Insider Sale: Chief Transformation Officer Lauren Duprey Sells 34,535 Shares
Takeda Pharmaceutical Company Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Leadership transition and a new strategic phase are underway, with a focus on deep pipeline investment and upcoming launches like ORZEYFUL and zasocitinib. Key data readouts for TAK-360 and IBD indications are expected by the end of the fiscal year, supporting a steady flow of future launches.
Takeda's Zasocitinib NDA Gets FDA Priority Review For Plaque Psoriasis; PDUFA Date Set For Q1' 27
(RTTNews) - Takeda Pharmaceutical Company Limited (TAK), on Monday reported that the U.S. Food and Drug Administration (FDA) has accepted Zasocitinib's New Drug Application (NDA) under priority review...
Takeda announces FDA acceptance of zasocitinib under priority review
Takeda (TAK) announced that the FDA accepted its new drug application, or NDA, under priority review for zasocitinib for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib i...
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda's Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review fo...
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
MALMO, Sweden & WILMINGTON, Del.--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place Septem...
Takeda announces publication of data from Phase 3 studies of oveporexton
Takeda (TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton, an oral orexin receptor 2 agonist, in people with narcolepsy type…
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton (ORZEY...
Keros Therapeutics Authorises $ 5 Mln Share Buyback Following Elritercept Milestone; Stock Up
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company announced that its board approved a $5 million share repurchase program after receiving a $20 million elritercep...
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...
Weave Bio Announces Collaboration with Takeda to Deploy AI-Native Regulatory Automation Across Key Drug Development Activities
SAN FRANCISCO--(BUSINESS WIRE)-- #AI--Weave Bio, the leader in AI-native regulatory automation for drug development, today announced a collaboration with Takeda to deploy the Weave platform across 14 ...
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
Nearly a dozen drugmakers are reportedly slated to voluntarily sell their medications at lower prices under deals expected to be announced by President Donald Trump on Monday. The string of deals buil...
Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
Protagonist announces Takeda received U.S. FDA approval for MIMRYLO
Protagonist Therapeutics (PTGX) announced that Takeda (TAK) received U.S. Food and Drug Administration, FDA, approval for MIMRYLO, a subcutaneously delivered first-in-class hepcidin mimetic peptide fo...
FDA Approves Takeda's Mimrylo For Rare Blood Disorder Polycythemia Vera
(RTTNews) - The U.S. Food and Drug Administration approved Takeda Pharmaceutical's (TAK, TKPHF, 4502.T) Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder t...
Takeda receives FDA approval of NDA for Mimrylo
Takeda (TAK) announced U.S. FDA approval of the New Drug Application for Mimrylo for the treatment of erythrocytosis in adults with polycythemia vera, a blood cancer.
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for...
US FDA approves Takeda, Protagonist's drug for rare blood cancer
The U.S. Food and Drug Administration has approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer, the health regulator said o...
Takeda announces Japan MHLW approval for Orzeyful
Takeda (TAK) announced that the Japanese Ministry of Health, Labour and Welfare, or MHLW, approved the use of Orzeyful for the treatment of narcolepsy type 1 in adults. Orzeyful is…